InvestorsHub Logo
Followers 17
Posts 735
Boards Moderated 0
Alias Born 02/05/2004

Re: None

Tuesday, 06/18/2013 4:56:27 PM

Tuesday, June 18, 2013 4:56:27 PM

Post# of 346050
I emailed IR this today:

Hi Chris & Jay,

The below paragraph is from Peregrines website and it states that results are expected in the 1st half of 2013 which ends June 30Th, 2013. Are they still on track to release those results as per Peregrines own statement in the 1st half of 2013? Thank you in advance.

Front-line NSCLC: This randomized, open-label Phase II trial is evaluating bavituximab with paclitaxel and carboplatin versus paclitaxel and carboplatin in 86 front-line NSCLC patients. Patient enrollment in this trial has been completed with top-line data reported in March, 2012. Overall survival data from the trial, which is an event driven endpoint, is expected in the first half of 2013.

Their Response:
From: Chris Keenan <CKeenan@peregrineinc.com>
Date: Tue, 18 Jun 2013 20:39:03 +0000
To: I blanked this out for privacy reasons
Subject: RE: Front Line NSCLC

"If we have not changed our guidance in a Regulation Full Disclosure format then these timelines are maintained by the company."




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News